AU2012328388B2 - Treatment protocol of diabetes type 2 - Google Patents

Treatment protocol of diabetes type 2 Download PDF

Info

Publication number
AU2012328388B2
AU2012328388B2 AU2012328388A AU2012328388A AU2012328388B2 AU 2012328388 B2 AU2012328388 B2 AU 2012328388B2 AU 2012328388 A AU2012328388 A AU 2012328388A AU 2012328388 A AU2012328388 A AU 2012328388A AU 2012328388 B2 AU2012328388 B2 AU 2012328388B2
Authority
AU
Australia
Prior art keywords
treatment
patient
lixisenatide
pharmaceutical combination
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012328388A
Other languages
English (en)
Other versions
AU2012328388A1 (en
Inventor
Louise Silvestre
Elisabeth Souhami
Xiaodan Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of AU2012328388A1 publication Critical patent/AU2012328388A1/en
Application granted granted Critical
Publication of AU2012328388B2 publication Critical patent/AU2012328388B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2012328388A 2011-10-28 2012-10-26 Treatment protocol of diabetes type 2 Active AU2012328388B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11187169 2011-10-28
EP11187169.5 2011-10-28
PCT/EP2012/071271 WO2013060850A1 (en) 2011-10-28 2012-10-26 Treatment protocol of diabetes type 2

Publications (2)

Publication Number Publication Date
AU2012328388A1 AU2012328388A1 (en) 2014-05-15
AU2012328388B2 true AU2012328388B2 (en) 2017-06-15

Family

ID=47071308

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012328388A Active AU2012328388B2 (en) 2011-10-28 2012-10-26 Treatment protocol of diabetes type 2

Country Status (15)

Country Link
US (1) US20130296236A1 (enExample)
EP (1) EP2771024B1 (enExample)
JP (1) JP6329487B2 (enExample)
KR (1) KR101967941B1 (enExample)
CN (2) CN107693783A (enExample)
AU (1) AU2012328388B2 (enExample)
BR (1) BR112014010200A2 (enExample)
CA (1) CA2851690C (enExample)
IL (1) IL232251B (enExample)
IN (1) IN2014CN02616A (enExample)
MX (1) MX359329B (enExample)
MY (1) MY170713A (enExample)
RU (1) RU2014121386A (enExample)
SG (1) SG11201401175SA (enExample)
WO (1) WO2013060850A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2014209630A2 (en) * 2013-06-27 2014-12-31 Inspark Technologies, Inc. Systems, devices, and/or methods for identifying time periods of insufficient blood glucose testing
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
CA2932873A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
KR20160104726A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
AR103415A1 (es) * 2015-01-16 2017-05-10 Sanofi Aventis Deutschland Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
TWI748945B (zh) * 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2025124473A1 (zh) * 2023-12-12 2025-06-19 江苏恒瑞医药股份有限公司 Glp-1类似物治疗代谢疾病的方法及医药用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2329848A1 (en) * 2009-11-13 2011-06-08 Sanofi-Aventis Deutschland GmbH Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes
WO2012156299A1 (en) * 2011-05-13 2012-11-22 Sanofi-Aventis Deutschland Gmbh Lixisenatide as add-on therapy to basal insulin in type 2 diabetes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
AU2004267955A1 (en) * 2003-09-02 2005-03-10 Prosidion Ltd. Combination therapy for glycaemic control
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
BRPI1008836B8 (pt) * 2009-02-04 2021-06-22 Sanofi Aventis Deutschland dispositivo e método médicos para proporcionar informações de controle glicêmico
JP5980466B2 (ja) * 2009-11-13 2016-08-31 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
KR20110052990A (ko) * 2009-11-13 2011-05-19 사노피-아벤티스 도이칠란트 게엠베하 인슐린 글라르긴 및 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2329848A1 (en) * 2009-11-13 2011-06-08 Sanofi-Aventis Deutschland GmbH Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes
WO2012156299A1 (en) * 2011-05-13 2012-11-22 Sanofi-Aventis Deutschland Gmbh Lixisenatide as add-on therapy to basal insulin in type 2 diabetes

Also Published As

Publication number Publication date
MX2014005139A (es) 2014-08-27
JP6329487B2 (ja) 2018-05-23
BR112014010200A2 (pt) 2020-10-27
KR101967941B1 (ko) 2019-04-10
CA2851690C (en) 2022-07-26
IN2014CN02616A (enExample) 2015-06-26
EP2771024B1 (en) 2018-11-28
KR20140093935A (ko) 2014-07-29
EP2771024A1 (en) 2014-09-03
RU2014121386A (ru) 2015-12-10
JP2015501314A (ja) 2015-01-15
IL232251A0 (en) 2014-06-30
SG11201401175SA (en) 2014-09-26
HK1198577A1 (en) 2015-04-30
MY170713A (en) 2019-08-27
CA2851690A1 (en) 2013-05-02
WO2013060850A1 (en) 2013-05-02
CN107693783A (zh) 2018-02-16
AU2012328388A1 (en) 2014-05-15
CN104066441A (zh) 2014-09-24
IL232251B (en) 2019-10-31
MX359329B (es) 2018-09-25
US20130296236A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
CA2851690C (en) Treatment protocol of diabetes type 2
US20250134964A1 (en) Method for inducing weight loss in a type 2 diabetes mellitus patient
EP2707017B1 (en) Lixisenatide and metformin for treatment of diabetes type 2
US20220054594A1 (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2691109B1 (en) Prevention of hypoglycaemia in diabetes mellitus type 2 patients
EP2750699B1 (en) Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
HK1198577B (en) Treatment protocol of diabetes type 2
HK1194307B (en) Lixisenatide and metformin for treatment of diabetes type 2
HK1185807A (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
HK1185807B (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)